Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 1.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,111 shares of the medical instruments supplier’s stock after selling 290 shares during the period. Trillium Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $7,158,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. McClarren Financial Advisors Inc. lifted its position in Becton, Dickinson and Company by 4,900.0% in the second quarter. McClarren Financial Advisors Inc. now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 98 shares during the last quarter. Tucker Asset Management LLC purchased a new stake in Becton, Dickinson and Company in the first quarter valued at $37,000. Glass Jacobson Investment Advisors llc purchased a new stake in Becton, Dickinson and Company in the second quarter valued at $37,000. Altshuler Shaham Ltd purchased a new stake in Becton, Dickinson and Company in the second quarter valued at $38,000. Finally, Advisors Asset Management Inc. purchased a new stake in Becton, Dickinson and Company in the first quarter valued at $40,000. Institutional investors and hedge funds own 86.72% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX traded up $1.84 on Thursday, hitting $235.60. 117,104 shares of the company were exchanged, compared to its average volume of 1,172,715. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.81 and a current ratio of 1.31. The business’s fifty day moving average is $257.77 and its 200 day moving average is $261.01. Becton, Dickinson and Company has a fifty-two week low of $218.82 and a fifty-two week high of $287.32. The firm has a market capitalization of $68.35 billion, a P/E ratio of 47.13, a price-to-earnings-growth ratio of 1.90 and a beta of 0.55.

Want More Great Investing Ideas?

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $3.42 EPS for the quarter, meeting the consensus estimate of $3.42. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.02 billion. Becton, Dickinson and Company had a net margin of 7.66% and a return on equity of 13.91%. The company’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.75 earnings per share. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.83 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a $0.95 dividend. The ex-dividend date of this dividend is Thursday, December 7th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio is currently 73.39%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BDX. Piper Sandler reduced their target price on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating for the company in a report on Friday, November 10th. StockNews.com began coverage on shares of Becton, Dickinson and Company in a report on Thursday, October 5th. They issued a “hold” rating for the company. TheStreet cut shares of Becton, Dickinson and Company from a “b” rating to a “c+” rating in a report on Thursday, November 9th. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $295.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. Finally, Raymond James cut their price target on shares of Becton, Dickinson and Company from $304.00 to $269.00 and set an “outperform” rating for the company in a report on Friday, November 10th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $279.33.

Get Our Latest Report on Becton, Dickinson and Company

Insider Activity

In other news, EVP Richard Byrd sold 459 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total value of $125,986.32. Following the sale, the executive vice president now directly owns 3,444 shares in the company, valued at $945,309.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Claire Fraser sold 848 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $281.66, for a total transaction of $238,847.68. Following the transaction, the director now owns 21,608 shares of the company’s stock, valued at $6,086,109.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Richard Byrd sold 459 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total transaction of $125,986.32. Following the transaction, the executive vice president now directly owns 3,444 shares in the company, valued at approximately $945,309.12. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.